Where Does Context Therapeutics Inc (CNTX) Stock Fall in the Biotechnology Field After It Has Gained 21.37% This Week?

Context Therapeutics Inc (CNTX) is near the top in its industry group according to InvestorsObserver. CNTX gets an overall rating of 70. That means it scores higher than 70 percent of stocks. Context Therapeutics Inc gets a 82 rank in the Biotechnology industry. Biotechnology is number 18 out of 148 industries.

CNTX has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on CNTX!

See Full CNTX Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 70 means the stock is more attractive than 70 percent of stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Context Therapeutics Inc Stock Today?

Context Therapeutics Inc (CNTX) stock is up 2.9% while the S&P 500 is lower by -0.1% as of 10:15 AM on Monday, Apr 1. CNTX has risen $0.04 from the previous closing price of $1.38 on volume of 439,351 shares. Over the past year the S&P 500 has gained 27.27% while CNTX has risen 136.67%. CNTX lost -$1.50 per share the over the last 12 months. Click Here to get the full Stock Report for Context Therapeutics Inc stock.